Please login to the form below

Not currently logged in
Email:
Password:

Baxalta

This page shows the latest Baxalta news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s rare blood disorder drug Cablivi set for European approval

Sanofi’s rare blood disorder drug Cablivi set for European approval

Shire unit Baxalta got a green light for Veyvondi (vonicog alfa) for the treatment of von Willebrand disease, the most common inherited bleeding disorder.

Latest news

More from news
Approximately 16 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    quite as fast as Shire's move to take over Baxalta when it was spun out of Baxter in July 2015).

  • The good, the bad and the ugly The good, the bad and the ugly

    Shire’s incredible revenue growth of almost 57%, helped by its $32bn acquisition of Baxalta in 2016, lifted it into the top 20 for the first time in its history. ... However, investors fear that challenges in the $11bn haemophilia market could lead to

  • Accelerating innovation Accelerating innovation

    Going global. The company’s ambitions in cancer were boosted by last year’s appointment of new CEO David Meek, who joined the firm from Baxalta where he headed up that

  • Deal Watch January 2017 Deal Watch January 2017

    Interestingly 2016 had opened with Shire's announcement that the Baxalta acquisition was going ahead resulting in one of the year's biggest headlines with its final value of £32bn.

  • A rare talent A rare talent

    The biggest of these moves was its $32bn acquisition of Baxalta, which was officially completed in June last year and elevated its position in orphan drugs, which it expects to account ... The combination of Shire and Baxalta was extremely transformative,

More from intelligence
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Bedrock Healthcare Communications

    Abbvie. Baxalta. Baxter. Biogen. BMS. Britannia. CareFusion. Celgene. Ipsen. Janssen. Novartis.

  • FCB Halesway

    Abbott Vascular. Cardiovascular. Endovascular. Structural Heart. Baxalta. Haemophilia. Immunodeficiency. Bayer. Radiology solutions.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics